[ Inside the business ]

PODD stock analysis

PODD · Insulet Corp

Surgical and medical instruments and apparatus. Growing 19%. Keeps 18¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 1.2× sales in 5 yrs. Evidence: sales +19% · 18¢ profit/$1.

01 What's priced in?1.2× sales in 5 yrs
Sales now$3.2B
Needed in 5 yrs$3.7B
Backlog$5M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Distributor A: 27% of sales
Distributor A 27%Distributor B 26%Distributor C 25%Everyone else
Backlog $5M · under 0.1× salesPrepaid $17MSales +19%, steady
04 Is it scarce?Some signs
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 18¢ per $1, rising
'21'22'23'24'2518¢
Before running costs: 62% → 72%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −1.2%/yrDebt $19M
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the 10Y yield

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +34%, +24%, then +19% vs. a year ago. A leadership change was filed on Nov 20.

What could go wrong

Red flags.

It has moved 0.9× the market. In the 2008 crisis it fell 76% while the market fell 51%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

69% U.S. Omnipod.

U.S. Omnipod 69% · International Omnipod 31% · Drug Delivery 1%

Where each dollar goes

18¢ profit.

28¢ to make what it sells, 53¢ on research and overhead, 18¢ left over. Revenue $3.2B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Early maturity.

It earns cash, still invests, and pays back more than it borrows. Unusually, sales are still growing like a young company's.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

3 of 10 years.

Returns beat its 9.1% cost of capital in 3 of the last 10 years. Gross margin went from 58% to 72%.

Future bets

11% on research.

$360M a year on R&D. $249M on equipment and buildings.

All figures from Insulet Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.